{"id":212062,"date":"2026-03-24T00:08:57","date_gmt":"2026-03-24T00:08:57","guid":{"rendered":"https:\/\/teknomers.com\/en\/the-surge-of-generics-that-promises-to-lower-prices-in-some-countries\/"},"modified":"2026-03-24T00:08:58","modified_gmt":"2026-03-24T00:08:58","slug":"the-surge-of-generics-that-promises-to-lower-prices-in-some-countries","status":"publish","type":"post","link":"https:\/\/teknomers.com\/en\/the-surge-of-generics-that-promises-to-lower-prices-in-some-countries\/","title":{"rendered":"The Surge of Generics That Promises to Lower Prices in Some Countries"},"content":{"rendered":"\n
\n

The End of Ozempic’s Patent: A New Era for Generics<\/h2>\n

The drug Ozempic, known for its groundbreaking impact on the treatment of obesity and type 2 diabetes, is approaching a critical juncture: the expiration of its marketing patent. Specifically, the patent on its active ingredient, semaglutide, lapses in March 2026 in several international markets. This opens up the opportunity for generic versions<\/a> of the drug, which promise affordability for countless patients.<\/p>\n

The Success of Ozempic<\/h2>\n

Developed by the Danish firm Novo Nordisk<\/a>, Ozempic was initially approved in 2017 for type 2 diabetes. However, the drug quickly gained notoriety for its off-label use in weight loss, even though it was originally intended as a diabetes treatment.<\/p>\n

Ozempic can lead to a weight loss of 15-20% of body weight<\/a>, alongside notable cardiovascular benefits. Despite this, the high cost of the medication remains a significant barrier for many patients. The introduction of generics could democratize access to this essential treatment, particularly for patients with severe obesity.<\/p>\n

Understanding Pharmaceutical Patents<\/h2>\n

Creating a new drug involves substantial financial investment, which is why pharmaceutical companies seek to maximize profits during the patent protection period. Typically, these patents last for 20 years. Once expired, other manufacturers can produce the same medication at lower prices, essentially serving as generic alternatives.<\/p>\n

The Global Impact of Patent Expiration<\/h3>\n

Since Novo Nordisk filed its base patent around 2006, the expiration timeline has been set for March 2026 in significant markets like India, China<\/a>, and Brazil. Manufacturers in these countries are already gearing up to release generics such as Obeda and GLIPIQ<\/a>, expecting to cut costs by 80-90%. This can bring treatment prices down to just $15 to $30 per month.<\/p>\n

The Situation in Spain<\/h2>\n

Unfortunately, patients in Spain may have to wait longer for affordable alternatives. In the European Union and the United States, legal frameworks, such as the Complementary Protection Certificate<\/a>, extend the exclusivity period. This means Novo Nordisk\u2019s monopoly in Spain will persist until March 2031 while it may last until 2033 in the United States. Given that approximately 19% of adults in Spain are categorized as obese, the healthcare system faces increasing pressure to finance treatments like Ozempic.<\/p>\n

Novo Nordisk\u2019s Response<\/h2>\n

As generics emerge in the market, Novo Nordisk is not resting on its laurels. The company is actively looking to develop more effective oral versions that contain a higher concentration of semaglutide. Its new flagship product, called CagriSema, combines GLP-1 and amylin to enhance weight-loss benefits, a strategic move to retain market share as the patent period ends.<\/p>\n

As the landscape for obesity and diabetes treatments shifts in 2026, the rise of generics presents both challenges and opportunities. While patients in many countries will benefit from lower prices, the question of accessibility remains critical in regions like Europe, highlighting the ongoing need for equitable healthcare solutions.<\/p>\n<\/div>\n


\n
General News – 2<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

The End of Ozempic’s Patent: A New Era for Generics The drug Ozempic, known for its groundbreaking impact on the treatment of obesity and type 2 diabetes, is approaching a critical juncture: the expiration of its marketing patent. Specifically, the patent on its active ingredient, semaglutide, lapses in March 2026 in several international markets. This […]<\/p>\n","protected":false},"author":1,"featured_media":212063,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36399],"tags":[30,50417,767,564,25314],"class_list":["post-212062","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology","tag-countries","tag-generics","tag-prices","tag-promises","tag-surge"],"_links":{"self":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts\/212062","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/comments?post=212062"}],"version-history":[{"count":1,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts\/212062\/revisions"}],"predecessor-version":[{"id":212064,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts\/212062\/revisions\/212064"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/media\/212063"}],"wp:attachment":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/media?parent=212062"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/categories?post=212062"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/tags?post=212062"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}